- SIGA Technologies (NASDAQ:SIGA) on Tuesday said it had got orders worth about $28M for its oral smallpox treatment TPOXX (tecovirimat).
- TPOXX was approved as a treatment for smallpox by the U.S. FDA in 2018 and Canada's drug regulator in 2021. The European drug regulator in Jan. 22 approved TPOXX with a broader label covering the treatment of smallpox, monkeypox and cowpox.
- TPOXX has been in demand since the monkeypox outbreak started spreading in Europe and the U.S.
- SIGA in Tuesday's statement said that about $26M of the orders were received from Canada under existing procurement contracts.
- The remaining $2M worth of orders were received from two new international jurisdictions - one in Europe and one in the Asia Pacific region.
- SIGA said, year-to-date, it had got about $56M of international orders for oral TPOXX from six jurisdictions.
- The company expects at least $26M of international deliveries by Sept. 30.
- "The increase over the last two months in international orders of oral TPOXX (tecovirimat) reflects an initial public health reaction to the evolving monkeypox outbreak,” said SIGA CEO Phil Gomez.
- SIGA stock +3.2% to $13.43 in aftermarket trading.
Recommended For You
More Trending News
See More »